Literature DB >> 9327337

Elevated serum cyclophilin levels in patients with severe sepsis.

I Tegeder1, A Schumacher, S John, H Geiger, G Geisslinger, H Bang, K Brune.   

Abstract

Several cytokines are considered to be important mediators in the pathophysiology of sepsis. Cyclophilins (Cyps), the main binding proteins for the immunosuppressive drug cyclosporine A, have been suggested to function as cytokines. This study was conducted to determine (i) if serum Cyp levels were elevated in critically ill patients suffering from either sepsis or other life-threatening diseases and (ii) if so, whether there was an association between Cyp levels and a certain diagnosis and/or outcome. Serum samples of 45 patients (22 severe sepsis, 23 other diagnoses) and 17 healthy controls were prospectively analyzed by an enzymatic assay using the ability of cyclophilins to catalyze cis/trans isomerisation of peptidylprolyl-peptide bonds (PPIase activity). In addition, western blotting was applied to differentiate both isoforms. PPIase activity was significantly higher in patients with severe sepsis than in patients with other diagnoses (P = 0.004) or in healthy subjects (P = 0.001). There was no difference between healthy subjects and other critically ill patients (P = 0.067). Elevated PPIase activity was associated with high mortality (P = 0.03). It is concluded that Cyps might play a role, probably as mediators in the pathophysiology of sepsis or as symptoms of diagnostic value.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9327337     DOI: 10.1023/a:1027364207544

Source DB:  PubMed          Journal:  J Clin Immunol        ISSN: 0271-9142            Impact factor:   8.317


  29 in total

1.  Cleavage of structural proteins during the assembly of the head of bacteriophage T4.

Authors:  U K Laemmli
Journal:  Nature       Date:  1970-08-15       Impact factor: 49.962

2.  A cytosolic binding protein for the immunosuppressant FK506 has peptidyl-prolyl isomerase activity but is distinct from cyclophilin.

Authors:  J J Siekierka; S H Hung; M Poe; C S Lin; N H Sigal
Journal:  Nature       Date:  1989-10-26       Impact factor: 49.962

3.  Isolation and characterization of a 40-kDa cyclophilin-related protein.

Authors:  L J Kieffer; T Thalhammer; R E Handschumacher
Journal:  J Biol Chem       Date:  1992-03-15       Impact factor: 5.157

4.  Interleukin-8 is a cyclosporin A binding protein.

Authors:  H Bang; K Brune; C Nager; U Feige
Journal:  Experientia       Date:  1993-07-05

5.  Cyclophilin-facilitated bradykinin inactivation in the perfused rat lung.

Authors:  M P Merker; C A Dawson
Journal:  Biochem Pharmacol       Date:  1995-12-22       Impact factor: 5.858

6.  Inhibitory effect of plasma FKBP12 on immunosuppressive activity of FK506.

Authors:  Y Shirakata; M Kobayashi; K Ohtsuka; M Sugano; H Terajima; I Ikai; H Okajima; H Egawa; Y Inomata; T Inamoto
Journal:  Transplantation       Date:  1995-12-27       Impact factor: 4.939

7.  Cyclosporin A slows collagen triple-helix formation in vivo: indirect evidence for a physiologic role of peptidyl-prolyl cis-trans-isomerase.

Authors:  B Steinmann; P Bruckner; A Superti-Furga
Journal:  J Biol Chem       Date:  1991-01-15       Impact factor: 5.157

8.  Cyclophilin-A is a zinc-dependent DNA binding protein in macrophages.

Authors:  U Krummrei; R Bang; R Schmidtchen; K Brune; H Bang
Journal:  FEBS Lett       Date:  1995-08-28       Impact factor: 4.124

9.  [Determination of enzymatic catalysis for the cis-trans-isomerization of peptide binding in proline-containing peptides].

Authors:  G Fischer; H Bang; C Mech
Journal:  Biomed Biochim Acta       Date:  1984

10.  Presence of cyclophilin A in synovial fluids of patients with rheumatoid arthritis.

Authors:  A Billich; G Winkler; H Aschauer; A Rot; P Peichl
Journal:  J Exp Med       Date:  1997-03-03       Impact factor: 14.307

View more
  37 in total

1.  Blocking cyclophilins in the chronic phase of asthma reduces the persistence of leukocytes and disease reactivation.

Authors:  Erik J Stemmy; Molly A Balsley; Rosalyn A Jurjus; Jesse M Damsker; Michael I Bukrinsky; Stephanie L Constant
Journal:  Am J Respir Cell Mol Biol       Date:  2011-04-14       Impact factor: 6.914

2.  A cell-impermeable cyclosporine A derivative reduces pathology in a mouse model of allergic lung inflammation.

Authors:  Molly A Balsley; Miroslav Malesevic; Erik J Stemmy; Jason Gigley; Rosalyn A Jurjus; Dallen Herzog; Michael I Bukrinsky; Gunter Fischer; Stephanie L Constant
Journal:  J Immunol       Date:  2010-11-05       Impact factor: 5.422

3.  Novel approach to inhibit asthma-mediated lung inflammation using anti-CD147 intervention.

Authors:  William M Gwinn; Jesse M Damsker; Rustom Falahati; Ifeanyi Okwumabua; Ann Kelly-Welch; Achsah D Keegan; Christophe Vanpouille; James J Lee; Lindsay A Dent; David Leitenberg; Michael I Bukrinsky; Stephanie L Constant
Journal:  J Immunol       Date:  2006-10-01       Impact factor: 5.422

Review 4.  Cyclophilin-CD147 interactions: a new target for anti-inflammatory therapeutics.

Authors:  V Yurchenko; S Constant; E Eisenmesser; M Bukrinsky
Journal:  Clin Exp Immunol       Date:  2010-03-16       Impact factor: 4.330

5.  Octasaccharide is the minimal length unit required for efficient binding of cyclophilin B to heparin and cell surface heparan sulphate.

Authors:  Christophe Vanpouille; Agnès Denys; Mathieu Carpentier; Rachel Pakula; Joël Mazurier; Fabrice Allain
Journal:  Biochem J       Date:  2004-09-01       Impact factor: 3.857

6.  Cyclophilin A as a novel biphasic mediator of endothelial activation and dysfunction.

Authors:  Se-Hwa Kim; Susan M Lessner; Yumiko Sakurai; Zorina S Galis
Journal:  Am J Pathol       Date:  2004-05       Impact factor: 4.307

7.  Involvement of two classes of binding sites in the interactions of cyclophilin B with peripheral blood T-lymphocytes.

Authors:  A Denys; F Allain; M Carpentier; G Spik
Journal:  Biochem J       Date:  1998-12-15       Impact factor: 3.857

Review 8.  CD147 immunoglobulin superfamily receptor function and role in pathology.

Authors:  Kathryn T Iacono; Amy L Brown; Mark I Greene; Sandra J Saouaf
Journal:  Exp Mol Pathol       Date:  2007-09-07       Impact factor: 3.362

9.  Liver proteomics for therapeutic drug discovery: inhibition of the cyclophilin receptor CD147 attenuates sepsis-induced acute renal failure.

Authors:  James W Dear; Asada Leelahavanichkul; Angel Aponte; Xuzhen Hu; Stephanie L Constant; Stephen M Hewitt; Peter S T Yuen; Robert A Star
Journal:  Crit Care Med       Date:  2007-10       Impact factor: 7.598

10.  Isoform-specific inhibition of cyclophilins.

Authors:  Sebastian Daum; Michael Schumann; Sebastian Mathea; Tobias Aumüller; Molly A Balsley; Stephanie L Constant; Boris Féaux de Lacroix; Fabian Kruska; Manfred Braun; Cordelia Schiene-Fischer
Journal:  Biochemistry       Date:  2009-07-07       Impact factor: 3.162

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.